ZA201003902B - Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide - Google Patents
Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamideInfo
- Publication number
- ZA201003902B ZA201003902B ZA2010/03902A ZA201003902A ZA201003902B ZA 201003902 B ZA201003902 B ZA 201003902B ZA 2010/03902 A ZA2010/03902 A ZA 2010/03902A ZA 201003902 A ZA201003902 A ZA 201003902A ZA 201003902 B ZA201003902 B ZA 201003902B
- Authority
- ZA
- South Africa
- Prior art keywords
- indazole
- piperidin
- carboxamide
- phenyl
- pharmaceutically acceptable
- Prior art date
Links
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical class N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1033308P | 2008-01-08 | 2008-01-08 | |
| PCT/GB2009/000041 WO2009087381A1 (en) | 2008-01-08 | 2009-01-08 | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201003902B true ZA201003902B (en) | 2011-02-23 |
Family
ID=40404013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/03902A ZA201003902B (en) | 2008-01-08 | 2010-06-01 | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8436185B2 (OSRAM) |
| EP (1) | EP2240466B1 (OSRAM) |
| JP (1) | JP5989965B2 (OSRAM) |
| KR (1) | KR101653548B1 (OSRAM) |
| CN (2) | CN101932572A (OSRAM) |
| AU (1) | AU2009203598B2 (OSRAM) |
| BR (1) | BRPI0906020A2 (OSRAM) |
| CA (1) | CA2711491C (OSRAM) |
| ES (1) | ES2548131T3 (OSRAM) |
| FR (1) | FR18C1020I2 (OSRAM) |
| IL (1) | IL206201A (OSRAM) |
| MX (1) | MX337421B (OSRAM) |
| NL (1) | NL300938I2 (OSRAM) |
| NZ (1) | NZ586675A (OSRAM) |
| WO (1) | WO2009087381A1 (OSRAM) |
| ZA (1) | ZA201003902B (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045095A1 (en) | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds and methods of use |
| WO2010111063A1 (en) | 2009-03-21 | 2010-09-30 | Ning Xi | Amino ester derivatives, salts thereof and methods of use |
| JP5745283B2 (ja) | 2010-02-12 | 2015-07-08 | ファイザー・インク | ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体 |
| WO2014088983A1 (en) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| KR20170016498A (ko) | 2014-06-17 | 2017-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법 |
| IL283006B2 (en) | 2015-04-01 | 2023-10-01 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| WO2017056498A1 (ja) * | 2015-09-30 | 2017-04-06 | 国立大学法人東北大学 | 糖尿病性腎症の判定マーカー |
| PT3478286T (pt) | 2016-06-29 | 2024-01-31 | Tesaro Inc | Métodos de tratamento do cancro do ovário |
| RS66574B1 (sr) | 2016-07-29 | 2025-03-31 | Janssen Pharmaceutica Nv | Niraparib za upotrebu u postupku lečenja raka prostate |
| CN107663190B (zh) * | 2016-07-29 | 2020-06-09 | 钟桂发 | 一种尼拉帕尼及其中间体的制备方法以及中间体化合物 |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| EP3689419A1 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| SG10201913083SA (en) | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| WO2018183354A1 (en) | 2017-03-27 | 2018-10-04 | Tesaro, Inc. | Niraparib compositions |
| EP3606523A1 (en) * | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| US11384062B2 (en) | 2017-04-04 | 2022-07-12 | Combiphos Catalysts, Inc. | Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide |
| JOP20190244A1 (ar) | 2017-04-13 | 2019-10-13 | Janssen Pharmaceutica Nv | تركيبة علاجية لسرطان البروستاتا |
| AU2018258274C1 (en) | 2017-04-24 | 2021-12-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| KR102769634B1 (ko) | 2017-04-27 | 2025-02-19 | 테사로, 인코포레이티드 | 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도 |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) * | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| CN108530425A (zh) * | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| CN109081828B (zh) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| US10927095B2 (en) | 2017-08-14 | 2021-02-23 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of Niraparib and intermediates thereof |
| US20200271666A1 (en) * | 2017-09-13 | 2020-08-27 | B.R.A.H.M.S Gmbh | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
| WO2019053116A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | FLUID THERAPY GUIDING METHOD BASED ON PROADRENOMEDULLINE |
| US20200264199A1 (en) * | 2017-09-13 | 2020-08-20 | B.R.A.H.M.S Gmbh | Pct and pro-adm as markers for monitoring antibiotic treatment |
| EP3687505A1 (en) | 2017-09-26 | 2020-08-05 | Tesaro Inc. | Niraparib formulations |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| MX2020003799A (es) * | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| WO2019133697A1 (en) | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Methods of treating cancer |
| EP3749352A1 (en) | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| CN118994103A (zh) * | 2018-10-03 | 2024-11-22 | 特沙诺有限公司 | 尼拉帕利盐 |
| US12297184B2 (en) | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| WO2020072860A1 (en) * | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| WO2020225753A2 (en) | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN110407704B (zh) * | 2019-08-19 | 2022-05-17 | 常州沃腾化工科技有限公司 | 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法 |
| MX2022014003A (es) | 2020-05-08 | 2022-11-30 | Janssen Pharmaceutica Nv | Tratamientos del cancer de prostata con combinaciones de acetato de abiraterona y niraparib. |
| US20240325369A1 (en) | 2021-07-19 | 2024-10-03 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| EP4472634A1 (en) | 2022-02-04 | 2024-12-11 | JANSSEN Pharmaceutica NV | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| WO2024238587A1 (en) | 2023-05-17 | 2024-11-21 | Tesaro, Inc. | Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer |
| WO2025027138A1 (en) | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
| CN117843713A (zh) * | 2023-12-18 | 2024-04-09 | 上海亲合力生物医药科技股份有限公司 | 基于肿瘤微环境激活的激酶抑制剂、组合物及应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| AT401651B (de) * | 1994-06-14 | 1996-11-25 | Biochemie Gmbh | 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4- |
| JPH11510154A (ja) * | 1995-08-02 | 1999-09-07 | ニューキャッスル ユニバーシティ ベンチャーズ リミテッド | ベンズイミダゾール化合物 |
| CA2332279A1 (en) | 1998-05-15 | 1999-11-25 | Jia-He Li | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| EP1124805B1 (de) | 1998-10-30 | 2003-05-21 | Lonza AG | Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen |
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| RU2001116581A (ru) | 1998-11-17 | 2004-02-20 | БАСФ Акциенгезельшафт (DE) | Замещенные 2-фенилбензимидазолы и 2-фенилиндолы, их получение и применение |
| RU2001117757A (ru) * | 1998-11-27 | 2004-02-27 | БАСФ Акциенгезельшафт (DE) | Замещенные бензимидазолы и их применение в качестве ингибиторов поли(аденозиндифосфатрибоза)полимеразы |
| DE19918211A1 (de) * | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| WO2001021615A1 (fr) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
| US6508365B1 (en) * | 1999-12-28 | 2003-01-21 | Pitney Bowes Inc. | Method of removing mail from a mailstream using an incoming mail sorting apparatus |
| AU2001240542A1 (en) * | 2000-02-01 | 2001-08-14 | Basf Aktiengesellschaft | Heterocyclic compounds and their use as parp inhibitors |
| DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| WO2002068407A1 (en) | 2001-02-28 | 2002-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole compound |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003062234A1 (en) | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Quinoxaline compounds |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| WO2004014861A1 (ja) | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キノリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| CN1852893A (zh) * | 2003-07-21 | 2006-10-25 | 史密丝克莱恩比彻姆公司 | (2S,4S)－4－氟－1－[4－氟－β－(4－氟苯基)－L－苯基丙氨酰基]－2－吡咯烷甲腈对甲苯磺酸盐及其无水晶体形式 |
| WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| WO2005066136A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
| KR100876520B1 (ko) | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법 |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| WO2006110683A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| BRPI0611707A2 (pt) | 2005-06-29 | 2012-04-24 | Compumedics Ltd | conjunto de sensor com ponte condutiva |
| ES2378692T3 (es) | 2005-09-29 | 2012-04-17 | Abbott Laboratories | Las 1H-benzimidazol-4-carboxamidas sustituidas con fenilo en la posición 2 son potentes inhibidores de PARP |
| EP1966157B1 (en) * | 2005-11-15 | 2010-03-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| JP4611441B2 (ja) * | 2006-04-03 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
| ATE553104T1 (de) * | 2006-05-02 | 2012-04-15 | Abbott Lab | Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US7892667B2 (en) * | 2006-09-13 | 2011-02-22 | Altek Corporation | Battery security device |
| RS51780B (sr) * | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| JP2008228154A (ja) * | 2007-03-15 | 2008-09-25 | Fujitsu Ltd | 表示装置，および遠隔操作装置 |
-
2009
- 2009-01-08 NZ NZ586675A patent/NZ586675A/en unknown
- 2009-01-08 ES ES09700579.7T patent/ES2548131T3/es active Active
- 2009-01-08 AU AU2009203598A patent/AU2009203598B2/en active Active
- 2009-01-08 KR KR1020107015011A patent/KR101653548B1/ko active Active
- 2009-01-08 JP JP2010541101A patent/JP5989965B2/ja active Active
- 2009-01-08 WO PCT/GB2009/000041 patent/WO2009087381A1/en not_active Ceased
- 2009-01-08 BR BRPI0906020-0A patent/BRPI0906020A2/pt not_active Application Discontinuation
- 2009-01-08 US US12/811,922 patent/US8436185B2/en active Active
- 2009-01-08 CN CN2009801018616A patent/CN101932572A/zh active Pending
- 2009-01-08 EP EP09700579.7A patent/EP2240466B1/en active Active
- 2009-01-08 MX MX2010006593A patent/MX337421B/es active IP Right Grant
- 2009-01-08 CN CN201610345956.4A patent/CN106008460B/zh active Active
- 2009-01-08 CA CA2711491A patent/CA2711491C/en active Active
-
2010
- 2010-06-01 ZA ZA2010/03902A patent/ZA201003902B/en unknown
- 2010-06-06 IL IL206201A patent/IL206201A/en active Protection Beyond IP Right Term
-
2018
- 2018-05-14 FR FR18C1020C patent/FR18C1020I2/fr active Active
- 2018-05-15 NL NL300938C patent/NL300938I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5989965B2 (ja) | 2016-09-07 |
| RU2495035C2 (ru) | 2013-10-10 |
| WO2009087381A1 (en) | 2009-07-16 |
| RU2010133241A (ru) | 2012-02-20 |
| KR101653548B1 (ko) | 2016-09-02 |
| US20100286203A1 (en) | 2010-11-11 |
| US8436185B2 (en) | 2013-05-07 |
| EP2240466B1 (en) | 2015-07-29 |
| CA2711491A1 (en) | 2009-07-16 |
| BRPI0906020A2 (pt) | 2015-06-30 |
| MX337421B (es) | 2016-03-04 |
| CN101932572A (zh) | 2010-12-29 |
| FR18C1020I2 (fr) | 2019-06-07 |
| AU2009203598B2 (en) | 2013-09-26 |
| AU2009203598A1 (en) | 2009-07-16 |
| MX2010006593A (es) | 2010-12-21 |
| KR20100114021A (ko) | 2010-10-22 |
| FR18C1020I1 (OSRAM) | 2018-07-13 |
| IL206201A0 (en) | 2010-12-30 |
| CA2711491C (en) | 2016-03-08 |
| IL206201A (en) | 2014-07-31 |
| JP2011509252A (ja) | 2011-03-24 |
| EP2240466A1 (en) | 2010-10-20 |
| NZ586675A (en) | 2012-04-27 |
| CN106008460B (zh) | 2022-08-12 |
| CN106008460A (zh) | 2016-10-12 |
| ES2548131T3 (es) | 2015-10-14 |
| NL300938I2 (nl) | 2019-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201003902B (en) | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide | |
| IL197420A0 (en) | Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1- | |
| EP2244712A4 (en) | IN VIVO EXAMINATIONS OF CRYSTALLINE FORMS OF MELOXICAM | |
| IL209196A (en) | A crystalline form of posaconazole | |
| NL301214I2 (nl) | Lasmiditan en farmaceutisch aanvaardbare zouten daarvan | |
| AP2627A (en) | New form of administration of racecadotril | |
| IL219997A0 (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
| PL2503993T3 (pl) | Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1H-pirazol-3-ilo]oksy]etylo]morfoliny | |
| ZA201103495B (en) | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| WO2010055119A3 (en) | Pharmaceutical composition comprising pimobendan | |
| EP2195309A4 (en) | SALT POLYMORPHS OF THE ESOMEPRAZOLE | |
| EP2258705A4 (en) | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLONE, AN ANTI-INFECTIOUS | |
| IL208325A0 (en) | Stabilizing lipis compositions for oral pharmaceutical agents | |
| SI2303866T1 (sl) | Kristalne oblike natrijevega rabeprazolata | |
| ZA201003031B (en) | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465 | |
| IL200959A0 (en) | Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine | |
| EP2337565A4 (en) | STABLE SOLID ORAL CO DOSAGE FORMULATIONS | |
| ZA201008860B (en) | Pharmacokinetics of iontophorectic sumatriptan administration | |
| ZA201006548B (en) | Pyrimidylmethyl sulfonamide compounds | |
| HK40104059A (zh) | 来那替尼马来酸盐及晶形 | |
| HK40100457A (zh) | 来那替尼马来酸盐及晶形 | |
| HK40100458A (zh) | 来那替尼马来酸盐及晶形 | |
| IL219860A0 (en) | Oral formulation for dexlansoprazole | |
| EP2197446A4 (en) | PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE | |
| GB0808827D0 (en) | Novel pharmaceutically active compounds |